RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications
Diabetes mellitus is a metabolic disease that is characterized by chronic hyperglycemia due to a variety of etiological factors. Long-term metabolic stress induces harmful inflammation leading to chronic complications, mainly diabetic ophthalmopathy, diabetic cardiovascular complications and diabeti...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274654/full |
| _version_ | 1827782626466856960 |
|---|---|
| author | Dan Ke Dan Ke Zhen Zhang Zhen Zhang Jieting Liu Jieting Liu Peijian Chen Peijian Chen Yucen Dai Yucen Dai Xinhai Sun Yanhui Chu Luxin Li Luxin Li |
| author_facet | Dan Ke Dan Ke Zhen Zhang Zhen Zhang Jieting Liu Jieting Liu Peijian Chen Peijian Chen Yucen Dai Yucen Dai Xinhai Sun Yanhui Chu Luxin Li Luxin Li |
| author_sort | Dan Ke |
| collection | DOAJ |
| description | Diabetes mellitus is a metabolic disease that is characterized by chronic hyperglycemia due to a variety of etiological factors. Long-term metabolic stress induces harmful inflammation leading to chronic complications, mainly diabetic ophthalmopathy, diabetic cardiovascular complications and diabetic nephropathy. With diabetes complications being one of the leading causes of disability and death, the use of anti-inflammatories in combination therapy for diabetes is increasing. There has been increasing interest in targeting significant regulators of the inflammatory pathway, notably receptor-interacting serine/threonine-kinase-1 (RIPK1) and receptor-interacting serine/threonine-kinase-3 (RIPK3), as drug targets for managing inflammation in treating diabetes complications. In this review, we aim to provide an up-to-date summary of current research on the mechanism of action and drug development of RIPK1 and RIPK3, which are pivotal in chronic inflammation and immunity, in relation to diabetic complications which may be benefit for explicating the potential of selective RIPK1 and RIPK3 inhibitors as anti-inflammatory therapeutic agents for diabetic complications. |
| first_indexed | 2024-03-11T15:34:35Z |
| format | Article |
| id | doaj.art-edeee8a1eb5a4bcdad94b9f4ed5c082e |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-11T15:34:35Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-edeee8a1eb5a4bcdad94b9f4ed5c082e2023-10-26T23:30:44ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-10-011410.3389/fimmu.2023.12746541274654RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complicationsDan Ke0Dan Ke1Zhen Zhang2Zhen Zhang3Jieting Liu4Jieting Liu5Peijian Chen6Peijian Chen7Yucen Dai8Yucen Dai9Xinhai Sun10Yanhui Chu11Luxin Li12Luxin Li13College of Life Sciences, Mudanjiang Medical University, Mudanjiang, ChinaHeilongjiang Key Laboratory of Tissue Damage and Repair, Mudanjiang Medical University, Mudanjiang, ChinaHeilongjiang Key Laboratory of Tissue Damage and Repair, Mudanjiang Medical University, Mudanjiang, ChinaSchool of First Clinical Medical College, Mudanjiang Medical University, Mudanjiang, ChinaCollege of Life Sciences, Mudanjiang Medical University, Mudanjiang, ChinaHeilongjiang Key Laboratory of Tissue Damage and Repair, Mudanjiang Medical University, Mudanjiang, ChinaCollege of Life Sciences, Mudanjiang Medical University, Mudanjiang, ChinaHeilongjiang Key Laboratory of Tissue Damage and Repair, Mudanjiang Medical University, Mudanjiang, ChinaCollege of Life Sciences, Mudanjiang Medical University, Mudanjiang, ChinaHeilongjiang Key Laboratory of Tissue Damage and Repair, Mudanjiang Medical University, Mudanjiang, ChinaDepartment of Thoracic Surgery, Union Hospital, Fujian Medical University, Fuzhou, ChinaHeilongjiang Key Laboratory of Tissue Damage and Repair, Mudanjiang Medical University, Mudanjiang, ChinaCollege of Life Sciences, Mudanjiang Medical University, Mudanjiang, ChinaHeilongjiang Key Laboratory of Tissue Damage and Repair, Mudanjiang Medical University, Mudanjiang, ChinaDiabetes mellitus is a metabolic disease that is characterized by chronic hyperglycemia due to a variety of etiological factors. Long-term metabolic stress induces harmful inflammation leading to chronic complications, mainly diabetic ophthalmopathy, diabetic cardiovascular complications and diabetic nephropathy. With diabetes complications being one of the leading causes of disability and death, the use of anti-inflammatories in combination therapy for diabetes is increasing. There has been increasing interest in targeting significant regulators of the inflammatory pathway, notably receptor-interacting serine/threonine-kinase-1 (RIPK1) and receptor-interacting serine/threonine-kinase-3 (RIPK3), as drug targets for managing inflammation in treating diabetes complications. In this review, we aim to provide an up-to-date summary of current research on the mechanism of action and drug development of RIPK1 and RIPK3, which are pivotal in chronic inflammation and immunity, in relation to diabetic complications which may be benefit for explicating the potential of selective RIPK1 and RIPK3 inhibitors as anti-inflammatory therapeutic agents for diabetic complications.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274654/fulldiabetesdiabetic complicationsinflammationregulatory cell deathreceptor interacting protein kinase |
| spellingShingle | Dan Ke Dan Ke Zhen Zhang Zhen Zhang Jieting Liu Jieting Liu Peijian Chen Peijian Chen Yucen Dai Yucen Dai Xinhai Sun Yanhui Chu Luxin Li Luxin Li RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications Frontiers in Immunology diabetes diabetic complications inflammation regulatory cell death receptor interacting protein kinase |
| title | RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications |
| title_full | RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications |
| title_fullStr | RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications |
| title_full_unstemmed | RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications |
| title_short | RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications |
| title_sort | ripk1 and ripk3 inhibitors potential weapons against inflammation to treat diabetic complications |
| topic | diabetes diabetic complications inflammation regulatory cell death receptor interacting protein kinase |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274654/full |
| work_keys_str_mv | AT danke ripk1andripk3inhibitorspotentialweaponsagainstinflammationtotreatdiabeticcomplications AT danke ripk1andripk3inhibitorspotentialweaponsagainstinflammationtotreatdiabeticcomplications AT zhenzhang ripk1andripk3inhibitorspotentialweaponsagainstinflammationtotreatdiabeticcomplications AT zhenzhang ripk1andripk3inhibitorspotentialweaponsagainstinflammationtotreatdiabeticcomplications AT jietingliu ripk1andripk3inhibitorspotentialweaponsagainstinflammationtotreatdiabeticcomplications AT jietingliu ripk1andripk3inhibitorspotentialweaponsagainstinflammationtotreatdiabeticcomplications AT peijianchen ripk1andripk3inhibitorspotentialweaponsagainstinflammationtotreatdiabeticcomplications AT peijianchen ripk1andripk3inhibitorspotentialweaponsagainstinflammationtotreatdiabeticcomplications AT yucendai ripk1andripk3inhibitorspotentialweaponsagainstinflammationtotreatdiabeticcomplications AT yucendai ripk1andripk3inhibitorspotentialweaponsagainstinflammationtotreatdiabeticcomplications AT xinhaisun ripk1andripk3inhibitorspotentialweaponsagainstinflammationtotreatdiabeticcomplications AT yanhuichu ripk1andripk3inhibitorspotentialweaponsagainstinflammationtotreatdiabeticcomplications AT luxinli ripk1andripk3inhibitorspotentialweaponsagainstinflammationtotreatdiabeticcomplications AT luxinli ripk1andripk3inhibitorspotentialweaponsagainstinflammationtotreatdiabeticcomplications |